Agelessrx acarbose and Bexagliflozin - how many pills do you get per quarter?

#1

daily acarbose is $115 quarterly. Which is… doable I guess. But still way less than what I used to be able to do [b/c it often takes 100mg or more to really blunt spikes from some foods]. Knowing supply is being hit, I’ve stopped taking acarbose for beans (needing to preserve it for the occasions when I may anticipate eating bread)…

How easily do you get approved for it?

Will agelessrx be hit by the tariffs just as much as other companies will be?

AgelessRx Launches SGLT2 Inhibitor Therapy: A Clinically Backed Longevity Tool for Metabolic Reset and Anti-Aging Comtex. Their canagliflozin is very expensive… [at that rate just fly to Cancun to get empagliflozin]…

#2

Short answer: if you want outcome firepower and stronger glucose drop, empagliflozin wins. Bexagliflozin is fine for sugar, but it doesn’t have the same heart/kidney résumé.

Dimension Bexagliflozin (Brenzavvy) Empagliflozin (Jardiance)
Typical A1c drop at ~24 weeks −0.4% vs placebo (monotherapy) (FDA Access Data) −0.74% (10 mg) to −0.85% (25 mg) vs placebo (monotherapy) (PubMed)
Add-on to metformin −0.5% vs placebo (FDA Access Data) −0.70% (10 mg) to −0.77% (25 mg) vs placebo; −2.1 to −2.5 kg weight loss at 24 wks (PubMed)
Weight/BP effects ~−1.7 kg at 24 wks (BMI ≥25); SBP lower than glimepiride by ~6.8 mmHg in active-control trial (FDA Access Data) (FDA Access Data) Modest weight loss and BP reductions across trials; ~0.8% HbA1c drop with small weight loss is a fair rule of thumb (AHA Journals)
Hard outcomes (CV/renal) CV trial: no superiority for MACE (HR 0.77; 95% CI 0.56–1.08) (FDA Access Data) CV death/MACE benefit (EMPA-REG OUTCOME; primary HR ~0.86) and kidney protection (EMPA-KIDNEY) (American College of Cardiology)
Amputation signal Numerically higher non-traumatic amputations vs placebo in CV-risk trial (HR 1.64; CI crosses 1) (FDA Access Data) Not flagged like canagliflozin; standard class warnings apply; outcome trials did not show an amputation excess (American College of Cardiology)
Dosing & kidneys 20 mg once daily; not recommended if eGFR <30; contraindicated on dialysis (FDA Access Data) 10–25 mg once daily; broad HF/CKD indications independent of glucose control per label; glycemic effect wanes at low eGFR (FDA Access Data)

Bottom line in normal human words:

  • Glycemic punch: empagliflozin drops A1c more than bexagliflozin in like-for-like trials. (FDA Access Data)
  • Proven outcomes: empagliflozin has clear wins on heart and kidney endpoints; bexagliflozin doesn’t. (American College of Cardiology)
  • Safety quirks: same SGLT2 class stuff to watch (genital infections, volume depletion, rare DKA). Bexag’s CV-risk trial had more amputations numerically; handle foot risk factors accordingly. (FDA Access Data)

If you’re choosing a single SGLT2 for maximal overall benefit, pick empagliflozin unless there’s some very specific reason not to. If all you care about is a gentle glucose nudge with a once-daily pill, bexagliflozin will do that, but it’s the quiet cousin at the party.

2 Likes